Eli Lilly And Co vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Eli Lilly And Co trades at $1,220.55 (market cap $1.08T), while YieldMax Universe Fund of Option Income ETFs trades at $7.63. The key difference: Eli Lilly And Co pays a 0.57% dividend while YieldMax Universe Fund of Option Income ETFs pays none. Which is the better fit depends on your goals.
| LLY | YMAX | |
|---|---|---|
Market Cap | $1.08T | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.24K | $13.26 |
52-Week Low | $639.43 | $7.27 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
YMAX trades at $7.63, down 1.04% today, with a bullish technical signal but bearish moving averages. The ETF maintains a consistent weekly dividend distribution schedule, though recent news highlights concerns about fee structures impacting payouts. Key resistance and support levels are clustered around $8, with the RSI indicating potential overbought conditions on a short-term basis.
The outlook is mixed; the fund's income strategy provides regular distributions, but high embedded costs and reliance on market volatility for returns present risks. Upside depends on favorable option-writing conditions, while downside is linked to market stability and expense drag.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →